RYTELO - (EQ 47MG BASE/VIAL ; Powder)

Generic Name	IMETELSTAT SODIUM	**Innovator**	Geron
Dosage	EQ 47MG BASE/VIAL ; Powder	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

RYTELO - (EQ 188MG BASE/VIAL ; Powder)

Generic Name	IMETELSTAT SODIUM	**Innovator**	Geron
Dosage	EQ 188MG BASE/VIAL ; Powder	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.